Short Interest in Genmab A/S (OTCMKTS:GNMSF) Drops By 10.1%

Genmab A/S (OTCMKTS:GNMSF) was the target of a large decrease in short interest during the month of October. As of October 31st, there was short interest totalling 76,300 shares, a decrease of 10.1% from the October 15th total of 84,900 shares. Based on an average trading volume of 16,400 shares, the short-interest ratio is currently 4.7 days.

Genmab A/S Stock Performance

Shares of GNMSF traded down $7.79 during trading hours on Monday, hitting $212.71. 1,000 shares of the stock were exchanged, compared to its average volume of 2,488. Genmab A/S has a 12-month low of $202.30 and a 12-month high of $334.33. The company has a market cap of $13.90 billion, a price-to-earnings ratio of 20.45 and a beta of 1.07. The stock’s 50-day moving average price is $236.51 and its two-hundred day moving average price is $258.78.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.